Insulin Resistance, Type2 Diabetes Mellitus, Non-Alcoholic Fatty Liver Disease, Obesity
Conditions
Keywords
Hepatokines, High Fat Diet, Glycaemic Control, Fibroblast Growth Factor 21, Leukocyte Cell-derived Chemotaxin 2, Fetuin-A, Appetite, Ghrelin, Peptide YY
Brief summary
The present study will investigate the effect of high-fat overfeeding on a group of liver-secreted proteins linked to worsened blood sugar control, as well as proteins involved in appetite control. Participants will consume both a high-fat diet, consisting of 50% extra calories above their daily required intake, and a control diet, consisting of their normal 'habitual' diet, with each diet lasting seven days. The diets will be undertaken in a randomised order, with a period of three weeks separating the two diets. Blood samples will be taken before and after each diet to measure blood sugar control. Further blood samples will also be taken 24 hours and 72 hours into each diet to see how levels of the liver and appetite-regulating proteins change over the course of the seven days. It is expected that blood sugar control will be worsened by the high-fat diet and this will be accompanied by increases in levels of the liver-secreted proteins and an impaired release of the appetite-regulating proteins into the blood.
Detailed description
In recent years, researchers have identified a number of liver-secreted proteins, termed hepatokines, which are thought to play an important role in inter-organ crosstalk between the liver and other metabolically active tissues such as skeletal muscle and adipose tissue. Specifically, previous studies have demonstrated that hepatokines contribute to whole body glucose and lipid homeostasis through acting in an endocrine-like fashion. Understanding how circulating concentrations of these hepatokines can be manipulated in humans is essential, as impaired blood glucose and lipid control is a key feature of metabolic diseases, such as type 2 diabetes and non-alcoholic fatty liver disease. Previous research at Loughborough University has found that acute high-fat overfeeding for up to seven days can impair glycaemic control; however, the exact mechanisms responsible for these detrimental changes are not fully understood. Based upon previous evidence that hepatokine production is nutritionally modulated, the investigators believe that changes in hepatokine production may play a role in the detrimental metabolic effects seen following short-term, high-fat overfeeding which has implications for long-term metabolic health. Appetite regulation is also thought to play a role in the pathophysiology of obesity and insulin resistance, as the impaired secretion of several appetite regulatory hormones in both fasting and postprandial conditions has been observed in obesity, which is characterised by an chronic excessive energy intake. Therefore, the investigators are also interested to examine the appetite regulatory hormone response to short-term, high-fat overfeeding. The present study is a randomised, controlled, crossover study in which twelve recreationally active, healthy males will consume both a hypercaloric, high-fat diet (consisting of 50% extra energy above the daily requirement, 65% of which is fat) and a control diet (the participants' habitual diet) in a randomised fashion. A three-week washout period will separate the two diets in order to remove any lasting effects confounding the subsequent diet. Following a prescreening session in which anthropometric data will be collected, participants will commence their first dietary condition. An oral glucose tolerance test will be performed before and after the two diets to measure changes in glycaemic control/whole body insulin sensitivity. Further blood samples will be taken 24 hours and 72 hours after commencing the diets in order to observe the time course of any changes in circulating hepatokine and appetite hormone concentrations. Physical activity will also be monitored for the duration of the two dietary conditions to ensure that habitual physical activity levels are maintained.
Interventions
DIETARY_SUPPLEMENTHigh-fat diet
The high-fat diet will provide 7 days of overfeeding comprising of: +50% extra calories above the daily required intake, 65% of which is fat.
Sponsors
Nottingham Trent University
Nottingham University Hospitals NHS Trust
Loughborough University
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
NONE
Intervention model description
The study design is a randomised, controlled, crossover design in which participants undertake two 7-day dietary conditions in a randomised order with a three week washout period in between.
Eligibility
Sex/Gender
MALE
Age
18 Years to 40 Years
Healthy volunteers
Yes
Inclusion criteria
* Recreationally active - ≤ 2 structured exercise sessions per week * BMI between 18.5 - 27.9 kg/m2 * Body fat percentage \< 20% * Metabolically healthy - No known cardiovascular or metabolic disease such as diabetes, respiratory or heart disease. * Non-smoker * Weight stable in the past 6 months * Normal fasting blood glucose levels (3.6 - 5.5 mmol/l)
Exclusion criteria
* Contraindications to exercise * Needle Phobia
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Leukocyte cell-derived chemotaxin 2 (LECT2) | Baseline, 1 day, 3 days, 7 days | Time-course of LECT2 plasma concentrations across the 7-day dietary interventions |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Fetuin-A | Baseline, 1 day, 3 days, 7 days | Time-course of Fetuin-A plasma concentrations across the 7-day dietary interventions |
| Acylated ghrelin | Baseline, 1 day, 3 days, 7 days | Time-course of acylated ghrelin plasma concentrations across the 7-day dietary interventions |
| Peptide YY (PYY) | Baseline, 1 day, 3 days, 7 days | Time-course of PYY plasma concentrations across the 7-day dietary interventions |
| C-Terminal Telopeptide of Type 1 Collagen (CTX) | Baseline, 1 day, 3 days, 7 days | Time-course of CTX plasma concentrations across the 7-day dietary interventions |
| N-Terminal Propeptide of Type 1 Procollagen (P1NP) | Baseline, 1 day, 3 days, 7 days | Time-course of P1NP plasma concentrations across the 7-day dietary interventions |
| Visual Analogue Scale for Subjective Ratings of Appetite | Baseline, 1 day, 3 days, 7 days | Time-course of subjective ratings of hunger across the 7-day dietary interventions, measured using an appetite visual analogue scale. The scale is divided into subscales of different appetite perceptions including: hunger, fullness, satisfaction and prospective food consumption. Each subscale is rated on a 100mm scale (i.e. from 0 - 100), with a rating of 100 fully supporting the perception and a rating of 0 fully opposing the perception. |
| Subjective food preference | Baseline, 1 day, 3 days, 7 days | Time-course of subjective food preference across the 7-day dietary interventions, measured using the Leeds Food Preference Questionnaire. |
| Whole-body insulin sensitivity | Baseline, 7 Days | Changes in whole-body insulin sensitivity using the Matsuda Index, calculated from plasma glucose and insulin concentrations during the oral glucose tolerance test |
| Fibroblast growth factor 21 (FGF21) | Baseline, 1 day, 3 days, 7 days | Time-course of FGF21 plasma concentrations across the 7-day dietary interventions |
| Adipose tissue insulin resistance (ADIPO-IR) | Baseline, 1 day, 3 days, 7 days | Changes in ADIPO-IR using baseline concentrations of plasma insulin and non-esterified free fatty acids. |
| Physical activity and sedentary behaviour | 7 days (per diet) | Amounts of sitting time, standing time, light activity and moderate-vigorous activity will be measured across the duration of each diets to compare between the two. This will be Measured using Acitgraph and ActivPAL monitors. |
| Resting Metabolic Rate | Baseline, 7 Days | Changes in resting metabolic rate in response to the diets will be measured using indirect calorimetry and estimated using the Haldane transformation. |
| Fat Oxidation | Baseline, 7 Days | Changes in fat oxidation in response to the diets will be measured using indirect calorimetry and estimated using the Haldane transformation. |
| Blood pressure | Baseline, 1 day, 3 days, 7 days | Changes in blood pressure (systolic and diastolic) across the two dietary interventions will be measured using an automated pressure cuff. |
| Body weight | Baseline, 1 day, 3 days, 7 days | Changes in body weight across the two dietary interventions. |
| Body fat percentage | Baseline, 7 Days | Changes in body fat percentage across the two dietary interventions using bioelectrical impedance analysis. |
| Homeostasis model assessment of insulin resistance (HOMA-IR) | Baseline, 1 day, 3 days, 7 days | Changes in HOMA-IR (a marker of hepatic insulin resistance) using baseline concentrations of plasma glucose and insulin. |
Countries
United Kingdom
Outcome results
None listed